Heart problems hit hopes for experimental Amgen, UCB bone drug

(Reuters) - Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news